Development of ease-of-use flow cytometric system for multi-pathogen detection
Lead Participant:
BECTON, DICKENSON AND COMPANY
Abstract
Sepsis kills 30 000 people in the UK and costs the NHS £400 million per year. It is little known outside the medical profession but is the third most common cause of death in hospitalised patients outside of heart disease and cancer. It happens when an infection in the bloodstream tips the immune system out of balance and this system starts to attack the body rather than protect it. Many infections can potentially trigger sepsis but rapid treatment with the right antibiotic can often prevent it turning into serious sepsis. The Technology Strategy Board is supporting a group of teaching hospitals (St Thomas’s & Newcastle) in their work with BD (a US Heathcare Company with a base in Oxford) to develop a rapid test which can help doctors choose the right treatment during the critical early stages of the disease. This will save lives and reduce the huge cost of sepsis to the NHS.
Lead Participant | Project Cost | Grant Offer |
---|---|---|
BECTON, DICKENSON AND COMPANY | £1,509,351 | £ 410,000 |
  | ||
Participant |
||
NEWCASTLE UNIVERSITY | ||
UNIVERSITY OF NEWCASTLE | £249,550 | £ 249,550 |
KING'S COLLEGE LONDON | £433,324 | £ 433,324 |
INNOVATE UK | ||
KING'S COLLEGE LONDON BUSINESS LTD |
People |
ORCID iD |
Jim Keenan (Project Manager) |